Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.
Source: Getty Images Drs Uzzo, Chung, and Croll of Fox Chase Cancer Center at Temple University Health discuss top presentations from the ASCO Genitourinary Cancers Symposium 2026. The American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results